公司資料
KalVista Pharmaceuticals, Inc. 股價、新聞與催化劑
- 股票代碼:
- KALV
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom
股票表現
26.95 USD (+0.04%)
收盤價
最後更新: 2026年6月3日
1.43B USD
市值
股價為何變動
Current closing-price context is not available for KALV.
公司概覽
Hereditary Angioedema Company
KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks.
EKTERLY
EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is approved in multiple countries for patients age 12 and older and is commercialized directly or through regional partners.
Pediatric Expansion
The Phase 3 KONFIDENT-KID trial has completed enrollment in children ages 2–11. KalVista plans to use the study to extend oral on-demand treatment to younger patients and pursue additional global filings.
未來催化劑
- U.S. NDA filing for EKTERLY in children ages 2–11 planned for the third quarter of 2026.
- Potential U.S. pediatric launch anticipated in 2027, subject to approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。